Global Information
회사소개 | 문의 | 비교리스트

NTRK 융합 유전자 양성 진행성 고형암 시장 : 성장, 동향, COVID-19의 영향, 예측(2021-2026년)

NTRK Fusion Gene Positive Advanced Solid Tumor Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

리서치사 Mordor Intelligence Pvt Ltd
발행일 2022년 01월 상품코드 990487
페이지 정보 영문 배송안내 2-3일 (영업일 기준)
가격
US $ 4,750 ₩ 6,364,000 PDF & Excel (Single User License)
US $ 5,250 ₩ 7,033,000 PDF & Excel (Team License: Up to 7 Users)
US $ 6,500 ₩ 8,708,000 PDF & Excel (Site License)
US $ 8,750 ₩ 11,723,000 PDF & Excel (Corporate License)


NTRK 융합 유전자 양성 진행성 고형암 시장 : 성장, 동향, COVID-19의 영향, 예측(2021-2026년) NTRK Fusion Gene Positive Advanced Solid Tumor Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)
발행일 : 2022년 01월 페이지 정보 : 영문

본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문목차를 참고해주시기 바랍니다.

세계의 NTRK 융합 유전자 양성 진행성 고형암 시장 규모는 예측기간 중 약 5.4%의 CAGR로 성장할 것으로 예상됩니다.

시장 성장을 추진하고 있는 요인은 암 유병률 증가와 연구개발 활동 성장입니다. 세계적으로 암은 주요 사인의 하나입니다.

세계보건기구(WHO)는 향후 20년간 암 환자수가 70% 증가할 것으로 추정하고 있습니다. 또한 바이오마커는 위험 평가, 조기 진단 및 치료의 효과적인 모니터링에서 중요한 역할을 수행하기 때문에 몇 가지 생활습관 장애의 부담 증가도 시장을 견인할 것으로 예상됩니다.

신경영양성 티로신 수용체 키나아제(NTRK) 융합 유전자 양성 종양에 대한 엔트렉티닙의 FDA 승인은 암치료의 새로운 패러다임을 대표하고 있습니다. 암이 발생한 체내 위치에 기반하는 것이 아니라, 다양한 종양에서 보여지는 공통 바이오마커에 기반해 암을 치료합니다.

NTRK 융합 유전자 양성 진행성 고형암(NTRK Fusion Gene Positive Advanced Solid Tumor) 시장을 조사했으며, 시장 개요, 시장 성장 촉진요인 및 저해요인 분석, 종류별·최종사용자별·지역별 시장 규모 추정과 예측, 경쟁 상황, 주요 기업 개요, 시장 기회 등의 정보를 제공합니다.

목차

제1장 서론

제2장 조사 방법

제3장 주요 요약

제4장 시장 역학

  • 시장 개요
  • 시장 추진력
    • 암 유병률 증가
    • 성장하는 연구개발 활동
  • 시장 성장 억제요인
    • NTRK 융합 유전자의 유전자 스크리닝과 관련된 빈약한 헬스케어 인프라와 고비용
  • Porter's Five Forces 분석

제5장 시장 세분화

  • 종류별
    • 치료별
    • 진단별
  • 최종사용자별
    • 병원과 클리닉
    • 암센터
    • 기타
  • 지역별
    • 북미
    • 유럽
    • 아시아태평양
    • 중동과 아프리카
    • 남미

제6장 경쟁 상황

  • 기업 개요
    • Bayer AG
    • Teva Pharmaceuticals
    • Empire Genomics, LLC.
    • SeraCare Life Sciences
    • F. Hoffmann-La Roche Ltd
    • NeoGenomics Laboratories, Inc.
    • OncoDNA

제7장 시장 기회와 동향

KSM 21.03.05

The NTRK Fusion Gene Positive Advanced Solid Tumor market is anticipated to grow with a CAGR of nearly 5.4%, during the forecast period.

Certain factors that are driving the market growth include increasing prevalence of cancer and growing research and development activities. Globally, cancer is one of the leading causes of death. The disease witnessed significant growth in the last few decades, and it is expected to grow rapidly over the forecast period.

The World Health Organization (WHO) estimates the rate of cancer number to increase by 70% over the next two decades. Additionally, the increased burden of several lifestyle disorders is also expected to drive the market, as biomarkers play a vital role in risk assessment, early diagnosis, and effective monitoring of treatment.

FDA's approval of entrectinib for neurotrophic tyrosine receptor kinase (NTRK) fusion-positive tumors represents a new paradigm in cancer treatment. It treats a cancer based on a common biomarker seen across different tumors rather than based on the location in the body where the cancer originated.

Key Market Trends

Diagnostics Segment Holds Significant Share in the Global NTRK Fusion Gene Positive Advanced Solid Tumor Market

There are multiple methods for identifying NTRK fusions, including pan-TRK immunohistochemistry, fluorescence in situ hybridization and sequencing methods. FISH and RT-PCR have been successfully used in the clinic to detect NTRK fusions and are reasonable alternatives to NGS, especially for tumor histologies with a high prevalence of NTRK fusions involving recurrent partners (MASC, infantile fibrosarcomas, secretory breast carcinoma, and cellular or mixed congenital mesoblastic nephromas). Recent approvals add to the growth of the segment share. In 2018, SeraCare Life Sciences, a manufacturer and leading partner to global in vitro diagnostics manufacturers and clinical laboratories, launched an expanded neurotrophic tropomyosin receptor kinase (NTRK) RNA fusion reference material panel developed in a partnership with Bayer.

North America Dominates the Global NTRK Fusion Gene Positive Advanced Solid Tumor Market

As per the American Cancer Society, in 2018, the United States witnessed around 164,690 new cases of prostate cancer, causing over 26,430 deaths. About 60% of the total prostate cancer cases diagnosed are among men aged 65 years or older. In order to tackle such challenges, extensive research in the field of diagnostics has been undertaken.

The ease in the US government regulations and availability of funds from various organizations, like the National Institute of Health, have provided the potential for researchers to invest more in the use of fusion genes in drug discovery, drug development, detection of specific tumors, monitoring biological response to cancer therapy, and genetic studies for the identification of predisposed candidates of cancer.

Competitive Landscape

The global NTRK Fusion Gene Positive Advanced Solid Tumor market is competitive and consists of a few major players. Companies like Bayer AG, Cephalon, Inc., Empire Genomics, LLC., Exelixis, Inc, F. Hoffmann-La Roche Ltd, NeoGenomics Laboratories, Inc., OncoDNA, among others, hold the substantial market share in the market.

Additional Benefits:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 Study Deliverables
  • 1.2 Study Assumptions
  • 1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Increasing Prevalence of Cancer
    • 4.2.2 Growing Research and Development Activities
  • 4.3 Market Restraints
    • 4.3.1 Poor Healthcare Infrastructure and High Costs associated with Genetic Screening of NTRK Fusion Genes
  • 4.4 Porter's Five Force Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

  • 5.1 By Type
    • 5.1.1 By Therapeutics
    • 5.1.2 By Diagnostics
  • 5.2 By End-User
    • 5.2.1 Hospitals and Clinics
    • 5.2.2 Cancer Centers
    • 5.2.3 Others
  • 5.3 Geography
    • 5.3.1 North America
      • 5.3.1.1 United States
      • 5.3.1.2 Canada
      • 5.3.1.3 Mexico
    • 5.3.2 Europe
      • 5.3.2.1 Germany
      • 5.3.2.2 United Kingdom
      • 5.3.2.3 France
      • 5.3.2.4 Italy
      • 5.3.2.5 Spain
      • 5.3.2.6 Rest of Europe
    • 5.3.3 Asia-Pacific
      • 5.3.3.1 China
      • 5.3.3.2 Japan
      • 5.3.3.3 India
      • 5.3.3.4 Australia
      • 5.3.3.5 South Korea
      • 5.3.3.6 Rest of Asia-Pacific
    • 5.3.4 Middle-East and Africa
      • 5.3.4.1 GCC
      • 5.3.4.2 South Africa
      • 5.3.4.3 Rest of Middle-East and Africa
    • 5.3.5 South America
      • 5.3.5.1 Brazil
      • 5.3.5.2 Argentina
      • 5.3.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Bayer AG
    • 6.1.2 Teva Pharmaceuticals
    • 6.1.3 Empire Genomics, LLC.
    • 6.1.4 SeraCare Life Sciences
    • 6.1.5 F. Hoffmann-La Roche Ltd
    • 6.1.6 NeoGenomics Laboratories, Inc.
    • 6.1.7 OncoDNA

7 MARKET OPPORTUNITIES AND FUTURE TRENDS

Back to Top
전화 문의
F A Q